00:00 The PT KLB Pharma Tbk allocated capital expenditure of Rp1 trillion in 2024.
00:08 There are also Capex funds from internal cash flow.
00:12 Until the first quarter of 2024, the realization of Capex per share is still below Rp200 billion.
00:22 The PT KLB Pharma Tbk allocated capital expenditure of Rp1 trillion in 2024.
00:30 The funds are for additional capacity and maintenance in some facilities owned by the shareholders.
00:36 In the official statement, the company management explained that the Capex funds are from the internal cash flow of the shareholders in good condition.
00:43 Until the first quarter of 2024, the realization of Capex per share is still below Rp200 billion.
00:50 As reported in February, KLBF through the PT Global Owned Kaleb Pharma
00:55 is in the process of building a facility for the production of radioisotope and radiopharmacology,
01:00 especially fluorodeoxyglucose or FGD for the need to detect cancer diseases.
01:07 The radiopharmacology production facility that produces fluorodeoxyglucose or FGD
01:13 is very needed to support the inspection service of the tomography and computer tomography scanning position at the hospital.
Be the first to comment